Ortho-McNeil Pharmaceutical

Ortho-McNeil Pharmaceutical, in conjunction with the R.W. Johnson Pharmaceutical Research Institute uses radio labeled compounds for pharmaceutical research and development at their Spring House, PA facility. This manufacturing process yields a waste solution containing both radioactive material and an organic compound, which comprises a "mixed waste" under RCRA. The mixed waste is stored on site in accordance with a PA and EPA enforcement discretion policy for such wastes. Ortho-McNeil proposes to obtain superior environmental benefits through the use of an on-site bench-top catalytic oxidation process to treat the mixed waste, which would represent a more efficient, environmentally safe process as compared with current waste management and disposal practices.

Proposal Documents		Project Correspondence		Federal Register Notices
Final Project Agreement	Evaluation Documents		Other Information		Project Contacts

Ortho-McNeil Pharmaceutical

Local Navigation